FleuryBSP:FLRY3 +4.25%90 14-Day RSI is 67.44 as of Jul. 13, 2026. GuruFocus rates BSP:FLRY3 with a GF Score™ of 90/100 and a GF Value™ of R$17.47 (Fairly Valued). The stock has 5 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Fleury ranks worse than 94.93% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-13), Fleury's 14-Day RSI is 67.44.
The industry rank for Fleury's 14-Day RSI or its related term are showing as below:
BSP:FLRY3's 14-Day RSI is ranked worse than 94.93% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.06
vs BSP:FLRY3: 67.44
Fleury (BSP:FLRY3) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Fleury 14-Day RSI Related Terms
BSP:FLRY3 vs TMO, DHR, IDXX: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Fleury's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Fleury's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a 14-Day RSI of 67.44 as of Jul. 13, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fleury and its competitors. According to the industry distribution chart, Fleury ranks #206 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 94.9%.
Is Fleury's 14-Day RSI too high?
Fleury's current 14-Day RSI is 67.44. The Medical Diagnostics & Research industry median 14-Day RSI is 51.06. Fleury's value of 67.44 is 32.1% above this industry median. Based on the distribution chart, Fleury ranks #206 out of 217 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Fleury has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fleury's 14-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #206 out of 217 companies for 14-Day RSI. This places Fleury in the lower half of its industry. The industry median 14-Day RSI is 51.06. Fleury's value of 67.44 is 32.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 51.06, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current 14-Day RSI of 67.44 is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 51.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current 14-Day RSI is 67.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Fairly Valued. The stock's GF Value™ is R$17.47, compared to a current price of R$16.42 — trading 6% below its estimated fair value. The current 14-Day RSI is 67.44 and 32.1% above the Medical Diagnostics & Research industry median of 51.06. Fleury's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current 14-Day RSI is 67.44 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$16.42 is trading 6% below its estimated GF Value™ of R$17.47.
GuruFocus considers Fleury to be Fairly Valued.
Key valuation signals for BSP:FLRY3:
14-Day RSI: 67.44
GF Value™: R$17.47 vs. price of R$16.42 (6% below fair value)
Industry Position: 32.1% above the Medical Diagnostics & Research median (#206 of 217)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score
Get the complete analysis for BSP:FLRY3
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 